AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12459940
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg/day for 48 weeks)
Trial: 12459940
Drug: Etidronate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (200 mg/day for 2 weeks followed by 10-week medication-free periods)
Trial: 10673950
Drug: Standard patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard patient treatment position for left‐sided tumours
Trial: 10673950
Drug: 3-dimensional planning
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-dimensional planning with optimum treatment position for left‐sided tumours
Trial: 14671611
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Trial: 3900301
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy alone
Trial: 31383385
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral ibuprofen
Trial: 31383385
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral ibuprofen
Trial: 10223771
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral ibuprofen
Trial: 24613450
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral alendronate (70 mg)
Trial: 24613450
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (1-time 5 mg)
Trial: 19909947
Drug: Levonorgestrel (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (1.5 mg) administered orally
Trial: 19909947
Drug: Levonorgestrel (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (1.5 mg) administered vaginally
Trial: 7500174
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy nutrient dense supplement provided by a dietitian
Trial: 6349453
Drug: Real peritoneal
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real peritoneal dialysis (48 hours weekly, 1.5-hour cycle times, 2-litre exchanges by machine)
Trial: 6349453
Drug: Sham peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham peritoneal dialysis (recycling the same 2 litres of 1.5% continuous ambulatory peritoneal dialysis fluid, 1.5-hour cycle times for 48 hours weekly)
Trial: 27575034
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with triamcinolone (steroids)
Trial: 27575034
Drug: Bupivacaine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine without steroids (control)
Trial: 20717085
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose evaluation
Trial: 20717085
Drug: Average fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average fractional dose
Trial: 17713804
Drug: DHASCO-T capsules
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-T capsules at doses of 200 mg DHA per day
Trial: 17713804
Drug: DHASCO-T capsules
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-T capsules at doses of 600 mg DHA per day
Trial: 17713804
Drug: DHASCO-T capsules
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-T capsules at doses of 1,000 mg DHA per day
Trial: 17713804
Drug: DHASCO-S capsules
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-S capsules at doses of 200 mg DHA per day
Trial: 17713804
Drug: DHASCO-S capsules
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-S capsules at doses of 600 mg DHA per day
Trial: 17713804
Drug: DHASCO-S capsules
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHASCO-S capsules at doses of 1,000 mg DHA per day
Trial: 7808848
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms subunit vaccine
Trial: 7808848
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms subunit vaccine
Trial: 2766267
Drug: Psychoeducational preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational preparation 1‐2 days prior to surgery
Trial: 2766267
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no psychoeducational preparation)
Trial: 1130885
Drug: Clindamycin or
RxNorm normalized name: clindamycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin or Cephalothin (antibiotic therapy randomized, given intravenously prior to operation and for 5 days thereafter)
Trial: 31918232
Drug: Single‐ or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐ or mixed‐gender group therapy (for women)
Trial: 31918232
Drug: Mixed‐gender group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed‐gender group therapy (for men)
Trial: 26202996
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (cognitive-behavioral therapy)
Trial: 21447531
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of gelatin microspheres prepared with basic fibroblast growth factor (b‐FGF)
Trial: 21447531
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without any topical treatment
Trial: 16892912
Drug: Sequential and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential and multistage designs
Trial: 17989536
Drug: Venom immunotherapy
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venom immunotherapy
Trial: 15306668
Drug: No venom
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No venom immunotherapy
Trial: 8505011
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray (11 mg natural progesterone)
Trial: 8505011
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection (11 mg natural progesterone)
Trial: 3476985
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel followed by 1% NaF gel daily for 2 weeks
Trial: 3476985
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel followed by 1% NaF gel daily for 6 weeks supplemented twice with 8% SnF2 solution
Trial: 18701540
Drug: Static resting
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static resting splints plus standardized occupational therapy
Trial: 18701540
Drug: Standardized occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized occupational therapy alone
Trial: 15808245
Drug: Strontium plaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strontium plaque brachytherapy (Sr90) using plaque I (8 mm diameter, 15 Gy dose in 54 minutes)
Trial: 15808245
Drug: Strontium plaque
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strontium plaque brachytherapy (Sr90) using plaque II (4 mm diameter, 12.6 Gy dose in 11 minutes)
Trial: 6365467
Drug: Bemetizide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemetizide (25 mg) + Triamterene (50 mg)
Trial: 6365467
Drug: Cyclopenthiazide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopenthiazide (0.25 mg) + Potassium Chloride (600 mg)
Trial: 27821627
Drug: Rituximab with
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab with standard therapy
Trial: 22382410
Drug: Physical masking
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physical masking by spray-coating famotidine with ethyl cellulose
Trial: 22382410
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both taste-masking methods
Trial: 19302453
Drug: Individualized pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized pre-operative blood saving protocol (including strategies such as oral iron therapy, intravenous iron therapy, recombinant human erythropoietin alpha with i.v. iron, pre-operative autologous donation plus oral iron)
Trial: 17967591
Drug: Enoximone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (50 mg or 75 mg tid for 1 week, then reduced to 25 mg or 50 mg tid)
Trial: 1969066
Drug: Phosphate supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate supplementation (50 mg per day)
Trial: 30399024
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (2000 IU/day)
Trial: 23990341
Drug: Comparator (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (pooled intravenous standard therapies: semi-synthetic penicillin or vancomycin)
Trial: 21375959
Drug: Low-dose ultrasound
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ultrasound (0.5 W/cm2) delivered at 1 MHz, pulsed pattern of 1:4, applied to periulcer skin weekly for up to 12 weeks alongside standard care.
Trial: 21375959
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (low‐adherent dressings and compression therapy).
Trial: 19926050
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg once daily for 1 week
Trial: 19926050
Drug: Standard maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maintenance dosage clopidogrel (75 mg)
Trial: 17302062
Drug: Prunellae Oral
RxNorm normalized name: Prunella vulgaris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prunellae Oral Liquid (POL) based on classical therapy
Trial: 17302062
Drug: Classical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical therapy alone
Trial: 15566594
Drug: lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam (8 mg administered intravenously every 12 hours for six doses)
Trial: 2525023
Drug: Combined reflex-therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined reflex-therapy (including manipulations, neural therapy, and acupuncture)
Trial: 2525023
Drug: Usual ambulant
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual ambulant medicamentous physiotherapeutic treatment
Trial: 342295
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide 0.025% cream
Trial: 31446845
Drug: Optimised cardiopulmonary
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised cardiopulmonary bypass strategy (closed Cortiva® heparin‐coated circuit, low systemic heparinisation, intraoperative cell salvage)
Trial: 30948692
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (5 mg/day)
Trial: 27267689
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose beetroot juice (H-BT; 250 ml, n=10)
Trial: 27267689
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose beetroot juice (L-BT; 125 ml, n=9)
Trial: 27267689
Drug: Isocaloric placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric placebo (PLA; 250 ml, n=10)
Trial: 25881059
Drug: SMS-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS-based intervention for treatment adherence
Trial: 21957667
Drug: Salovum egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salovum egg yolk powder plus standard treatment
Trial: 19661012
Drug: metoprolol XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol XL 25 mg/chlorthalidone 6.25 mg
Trial: 19661012
Drug: metoprolol XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol XL 50 mg/chlorthalidone 12.5 mg
Trial: 19661012
Drug: metoprolol XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol XL 25 mg/HCTZ 12.5 mg
Trial: 19661012
Drug: metoprolol XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol XL 50 mg/HCTZ 12.5 mg
Trial: 16935462
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-thyroxine treatment)
Trial: 1390955
Drug: Haloperidol or
RxNorm normalized name: haloperidol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol or perazine (neuroleptic drugs)
Trial: 3909331
Drug: Aztreonam (1‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1‐2 g administered intravenously three or four times daily)
Trial: 3909331
Drug: Tobramycin (3‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (3‐5 mg/kg per day)
Trial: 29339395
Drug: Finafloxacin 800
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin 800 mg once a day for 5 days (FINA05)
Trial: 29339395
Drug: Finafloxacin 800
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin 800 mg once a day for 10 days (FINA10)
Trial: 29339395
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg/500 mg twice a day for 10 days (CIPRO10)
Trial: 27575452
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) with thoracic epidural levobupivacaine 0.12% plus sufentanil 0.4 µg/mL for 48 hours
Trial: 27575452
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration and continuous infusion with local anesthetics plus a single morphine bolus (CWI‐M) with 10 mL levobupivacaine 0.5% and levobupivacaine 0.25% infusion for 48 hours
Trial: 18375319
Drug: Intracoronary nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicardipine (1 mL, 0.1 mg)
Trial: 18375319
Drug: NaCl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (1 mL)
Trial: 11493736
Drug: G‐‐CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐‐CSF plus dexamethasone
Trial: 11493736
Drug: G‐‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐‐CSF alone
Trial: 2975227
Drug: Indobufen 200
RxNorm normalized name: indobufen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 200 mg
Trial: 31785250
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg of nalbuphine
Trial: 31785250
Drug: 2.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg/kg of sufentanil
Trial: 29952216
Drug: ENABLE CHF-PC
RxNorm normalized name: Enablex
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ENABLE CHF-PC intervention (in-person palliative care assessment, weekly telehealth coaching sessions, monthly follow-up)
Trial: 26043228
Drug: GLP-1 RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks
Trial: 26043228
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GLP-1 RA treatment)
Trial: 21641776
Drug: Adjunctive armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive armodafinil (150 mg/d)
Trial: 17012108
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (45 mg daily)
Trial: 17012108
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (45 mg daily) plus Vitamin D3 (0.75 microg 1alpha‐hydroxyvitamin D3 daily)
Trial: 15271700
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of 500 mL of a gelatin solution
Trial: 10669675
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by radiation therapy (60 Gy at 2.0 Gy per fraction)
Trial: 10669675
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation (1.2 Gy per fraction delivered twice daily to a total dose of 69.6 Gy)
Trial: 9193736
Drug: m‐CPP (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐CPP (0.25 mg/kg body weight)
Trial: 8437010
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg dextromethorphan daily for 12 weeks
Trial: 8437010
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dextromethorphan daily for up to 6 months
Trial: 30686699
Drug: Azithromycin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1,000 mg before LTx and 250 mg every other day from Day 1 to Day 31 after LTx)
Trial: 28606190
Drug: Public reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public reporting of prescription indicators monthly for one year
Trial: 21172721
Drug: AZD0837 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0837 150 mg
Trial: 21172721
Drug: AZD0837 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0837 300 mg
Trial: 21172721
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (no treatment, aspirin 75‐325 mg or clopidogrel 75 mg once daily)
Trial: 21172721
Drug: AZD0837 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0837 150 mg and 300 mg
Trial: 14742786
Drug: High-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin (80-90 mg/kg/d)
Trial: 14742786
Drug: Standard-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose amoxicillin (40-45 mg/kg/d)
Trial: 11275035
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (50 microg tablet every 4 hours for a maximum of six doses)
Trial: 11275035
Drug: Transcervical Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical Foley catheter (30‐mL Foley catheter placed transcervically with maintenance of traction)
Trial: 2420386
Drug: Dioctyl sodium
RxNorm normalized name: Dioctyl sodium sulfosuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctyl sodium sulfosuccinate (DS) administered 30 minutes before tetracycline and on -3, -2, and -1 day in the evening before tetracycline administration
Trial: 2420386
Drug: Tetracycline products
RxNorm normalized name: tetracycline Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline products (fast dissolving capsule, slow dissolving capsule, and suspension) without DS
Trial: 27405724
Drug: Promotion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promotion group (weekly emailed tips emphasizing social network interactions for walking)
Trial: 27405724
Drug: Activity group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity group (weekly tips + evidence‐based online fitness walking intervention)
Trial: 27405724
Drug: Social Networks
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Networks group (weekly tips + online networking site for walking)
Trial: 24786143
Drug: High-potency statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency statin regimen (simvastatin 40 mg/day for 1 month, then simvastatin 80 mg/day)
Trial: 24786143
Drug: Delayed moderate-potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed moderate-potency statin strategy (placebo for 4 months, then simvastatin 20 mg/day)
Trial: 19652922
Drug: Iron-supplemented group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-supplemented group (ISG) received 150 mg ferrous sulfate once weekly for 16 weeks.
Trial: 18813039
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg propofol plus 1.5 microg/kg remifentanil
Trial: 18813039
Drug: 4.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg/kg propofol plus 0.5 microg/kg remifentanil